Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
IL18	3606	THYROXINE	CHEMBL42115		NCI	16061828
IL18	3606	TACROLIMUS	CHEMBL269732		NCI	11061569
IL18	3606	ZIDOVUDINE	CHEMBL129		NCI	12559970
IL18	3606	DEXTRAN SULFATE SODIUM	CHEMBL2108952		NCI	16235535
IL18	3606	MYCOPHENOLIC ACID	CHEMBL866		NCI	12907250
IL18	3606	COLCHICINE	CHEMBL107		NCI	15281431

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
IL18	rs1946519	A	tacrolimus	metabolism/PK	no	This study was attempting to validate reported variants and tacrolimus trough concentration in a large population of African American and European American kidney transplant patients. This SNP is a proxy for rs1946518 (A-607C).	Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.	29318894	1449163245
IL18	rs1946518	T	interferon alfa-2a, recombinant	efficacy	yes	This association is for patients infected with viral genotype 1. Treatment was with 48 weeks of standard interferon-alpha-2a or interferon-alpha-2b plus ribavirin or pegylated interferon-alpha and ribavirin.	Allele T is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant, interferons, peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to allele G.	19455410	981865171
IL18	rs187238	CC	tacrolimus	metabolism/PK	no	Subjects (N=96) were administered a combination of tacrolimus, mycophenolate mofetil, and prednisone before kidney transplantation and the dose adjusted concentration of tacrolimus (C/D) ratio was assessed among subjects with different genotypes. There were no significant differences in C/D ratio of tacrolimus between genotypes. The same was observed in replication cohort (N=70).	Genotype CC is not associated with concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CG + GG.	25487141	1444666354
IL18	rs1946518	GT + TT	Tumor necrosis factor alpha	efficacy	yes	When comparing responders vs. non- and partial-responders. Patients with the TT genotype had increased response as compared to patients with the GG genotype, and patients with the GT + TT genotype had increased response as compared to patients with the GG genotype. However, no association was seen when compared GT vs GG, and no association was seen for any genotype when considering responders vs. non-responders.	Genotypes GT + TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotype GG.	28139755	1448604149
IL18	rs5744247	CC + CG	tacrolimus	metabolism/PK	yes	When considering DONOR liver genotype. There was a training set of individuals from Shanghai (n=84) and a validating set of individuals from Shandong (n=50). This result was significant at weeks 1 (p=0.017), 3 (p=0.011) and 4 (p=0.044) post-transplant, but not week 2 (p=0.157) in a training set. This result was significant at weeks 1 (p=0.0013) and 3 (p=0.0174) post-transplant, but not week 2 (p=0.4501) or 4 (p=0.0986) in a validating set. Multiple linear regression in both the training and validating sets showed that this SNP was an independent predictor of dose-adjusted trough concentrations, but only at week 1 (p=0.008 and p=0.033, respectively). Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype GG.	25712187	1444706053
IL18	rs5744247	CC + CG	tacrolimus	metabolism/PK	yes	Patients with the CC or CG genotypes had higher dose-adjusted trough concentrations of tacrolimus at weeks 1 (p=0.002), 2 (p=0.004), 3 (p=0.005) and 4 (p=0.026) post-transplant as compared to those with the GG genotype. This variant was also analyzed in combination with rs1946518 - patients with <=1 allele (Group 1), patients with 2 alleles (Group 2) and patients with >= 3 alleles (Group 3) were compared. Group 3 had lower dose-adjusted trough concentrations as compared to Groups 1 + 2 (p<0.05); no significant difference was seen between Groups 1 and 2. Additionally, note that this polymorphism had a significant impact among CYP3A5 expressers (rs776746 CT+TT) but NOT among nonexpressers (CC). Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype GG.	28246425	1448603535
IL18	rs5744247	C	tacrolimus	metabolism/PK	no	This study was attempting to validate reported variants and tacrolimus trough concentration in a large population of African American and European American kidney transplant patients.	Allele C is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.	29318894	1449163235
IL18	rs187238	C	interferon alfa-2a, recombinant	efficacy	yes	This association is for patients infected with viral genotype 1. Treatment was with 48 weeks of standard interferon-alpha-2a or interferon-alpha-2b plus ribavirin or pegylated interferon-alpha and ribavirin. The allele associated with non-response is not entirely clear, since this is a GC SNP. Paper reports G associated with higher rate of non-response. Gene is on the negative chromosomal strand, so it's likely that the allele associated (with decreased response) on the positive chromosomal strand is C.	Allele C is associated with decreased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant, interferons, peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to allele G.	19455410	981865177
IL18	rs1946518	GG + GT	tacrolimus	metabolism/PK	yes	Subjects (N=96) were administered a combination of tacrolimus, mycophenolate mofetil, and prednisone before kidney transplantation and the dose adjusted concentration of tacrolimus (C/D) ratio was assessed among subjects with different genotypes. There was a significant difference in tacrolimus C/D between the GG, GT and TT genotypes at week 3 after transplantation but not at week 1, 2 or 4. In a replication cohort (N=70) there were significant differences in tacrolimus C/D at week 1 and only marginally significant differences at week 3 and 4. When the impact of the polymorphism was assessed within the CYP3A5 expresser group (rs776746 CT+TT; CYP3A5 *1/*3 +*3/*3) the rs1946518 polymorphism was significantly associated with differences in tacrolimus C/D (rs1946518 is within the IL-18 gene, which modulates CYP3A5 expression). There were no significant differences in tacrolimus C/D by rs1946518 when comparing within the CYP3A5 non-expresser group.	Genotypes GG + GT are associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT.	25487141	1444666368
IL18	rs1946518	GG + GT	tacrolimus	metabolism/PK	yes	Dose-adjusted trough concentrations of tacrolimus were GG>GT>TT at weeks 1 (p=0.007), 2 (p=0.018) and 3 (p=0.019) post-transplant. No significant results were seen at week 4 (p=0.079). This variant was also analyzed in combination with rs5744247 - patients with <=1 allele (Group 1), patients with 2 alleles (Group 2) and patients with >= 3 alleles (Group 3) were compared. Group 3 had lower dose-adjusted trough concentrations as compared to Groups 1 + 2 (p<0.05); no significant difference was seen between Groups 1 and 2. Additionally, note that this polymorphism had a significant impact among CYP3A5 expressers (rs776746 CT+TT) but NOT among nonexpressers (CC). Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes GG + GT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype TT.	28246425	1448603543